Ganglioside GD1a Monoclonal Antibody (Clone MOG35)

Ganglioside GD1a (Item Nos. 31591 | 15585 | 31707) is a sialic acid-containing glycosphingolipid that has been found in brain, erythrocytes, bone marrow, testis, spleen, and liver, as well as in serum lipoproteins.{54332,54333} It is formed by the transfer of N-acetylneuraminic acid (Neu5Ac; Item No. 16091) to the precursor ganglioside GM1a by CMP-N-acetylneuraminate-?-galactosamide-?-2,3-sialyltransferase 2 (ST3Gal-II).{68400} It functions as a toll-like receptor 2 (TLR2) co-receptor in isolated human monocytes, colocalizing with TLR2 and enhancing the binding of type IIb E. coli enterotoxin (LT-IIb-B5) to TLR2.{25484} Ganglioside GD1a also mediates polyomavirus entry into host cells.{68401} Ganglioside GD1a is shed into the tumor microenvironment from the surface of tumor cells, where it influences tumor-host cell interactions to promote tumor cell proliferation, invasion, and metastasis, as well as increases VEGF-induced proliferation of human umbilical vein endothelial cells (HUVECs). A monoclonal antibody targeting ganglioside GD1a and ganglioside GT1b (Item Nos. 31712 | 15588 | 31592) inhibits axon regeneration in a mouse model of sciatic nerve crush-induced peripheral nervous system injury.{68402} Ganglioside GD1a accumulates in the CNS of patients with galactosialidosis, a lysosomal storage disorder.{43703} Cayman’s Ganglioside GD1a Monoclonal Antibody (Clone MOG35) can be used for dot blot, ELISA, immunofluorescence (IF), and TLC immunostaining applications.